Key facts
- It has raised $258.1M; the latest was Later Stage VC ($63.0M) in Sep 2025.
- Notable investors include Qiming Venture Partners, CDH Investments, YuanBio Venture Capital, Hankang Capital, Genesis Capital (Hong Kong) — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for AusperBio
- ·The full record, as it builds
Funding rounds
No funding rounds for AusperBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AusperBio
Manufacturer of oligonucleotide-based therapeutics focused on curing hepatitis B and treating a broad range of diseases through targeted delivery. The company specailises in liver-targeted delivery systems, metabolic disorder treatments, genetic disease therapies, immune modulation agents, preclinical validation models and structure-guided drug design tools, thereby improving treatment precision, reducing side effects and transforming patient outcomes.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2019
- Employees
- 100
- Website
- ausperbio.com/
- Ownership
- Privately Held (backing)
AusperBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AusperBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AusperBio in its N-PORT filings yet. We sweep new filings monthly.